Product Name: IL-31 Antibody (biotin)
Species Reactivity: Human
Tested Applications: ELISA, WB
Applications: ELISA:Direct:To detect hIL-31 by direct ELISA (using 100 μL/well antibody solution) a concentration of 0.25 – 1.0 μg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2 – 0.4 ng/well of recombinant hIL-31.SandwichTo detect hIL-31 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.25 – 1.0 μg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with our polyclonal Anti-Human IL-31 as a capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant hIL-31. Western Blot:To detect hIL-31 by Western Blot analysis this antibody can be used at a concentration of 0.1 – 0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-31 is 1.5 – 3.0 ng/lane, under either reducing or non-reducing conditions.
User Note: Centrifuge vial prior to opening.
Predicted Molecular Weight:
Immunogen: Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIL-31. Human IL-31 specific antibody was purified by affinity chromatography and then biotinylated.
Host Species: Rabbit
Purification:
Physical State: Lyophilized
CAS NO.: 27215-14-1
Product: Clebopride (malate)
Buffer:
Concentration:
Storage Conditions: IL-31 antibody is stable for at least 2 years from date of receipt at -20˚C. The reconstituted antibody is stable for at least two weeks at 2-8˚C. Frozen aliquots are stable for at least 6 months when stored at -20˚C. Avoid repeated freeze-thaw cycles.
Clonality: Polyclonal
Conjugate: Biotin
Alternate Names: IL-31Interleukin-31IL-31
Accession NO.: Q6EBC2
Protein Ino: 74709232
Official Symbol: IL31
Geneid: 386653
Background: Interleukin 31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia and skin lesions, and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
PubMed ID:http://aac.asm.org/content/26/3/421.abstract
